Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
UK-369, 003 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| UK-369,003 | DRUG | UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo. |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Male subjects aged 18 years and above * documented clinical diagnosis of overactive bladder with urinary frequency \>= 8 times / 24 hours and number of urgency episodes \> 1 episode / 24 hours. Exclusion Criteria: * Neurological diseases known to affect bladder function. * U...
UK-369,003 is an investigational small molecule being studied for male urogenital and pulmonary conditions, including erectile dysfunction (impotence), chronic obstructive pulmonary disease, benign prostatic hyperplasia, and overactive bladder. It is not approved and remains in clinical development.
UK-369,003 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. The company has sponsored clinical trials of the drug across multiple countries.
UK-369,003 is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, along with a Phase 1 drug interaction study.
UK-369,003 has been studied in several completed trials, including NCT00141349 in male erectile dysfunction, NCT00408954 in men with lower urinary tract symptoms, NCT00479505 in overactive bladder, and NCT00814736, a Phase 1 study with sildenafil.
No, UK-369,003 is a distinct investigational compound. A completed Phase 1 trial (NCT00814736) studied the safety and toleration of single-dose sildenafil in subjects receiving chronic UK-369,003, indicating they are separate drugs that may be used together.